MarketCapExport financials
Cutera (CUTR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Cutera Income Statement 2023-2008 | CUTR
Brief overview of revenue and earnings at Cutera
The figures are compared over a five-year interval. The revenue attributed to Cutera moved from $45.5 million to $49.5 million between the two endpoints. Overall revenue changed by +9%, equal to an annualized rate of about 1.7%. The scale of the core business was largely unchanged.
Gross profit changed from $80.4 million to −$12.7 million (−115.8%). The cost base moved against the top-line trend and weighed on the gross result. Gross margin moved from 176.8% to −25.6%. The margin decline reflects a less favorable sales-and-cost structure.
The operating result measured by EBITDA moved from −12.2 million dollars to −148 million dollars, or −1115.9%. Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from −26.8% to −299%. The business retained less EBITDA from each unit of revenue.
The net financial result changed from −30.8 million dollars to −57.2 million dollars. Profitability deteriorated further over the five years.
The five-year change in capitalization reached −80.5%: from $239 million to $46.5 million. Lower capitalization reflects weaker investor expectations.
Overall conclusion
The financial trajectory is weak and requires a cautious interpretation. Caution is warranted because of limited revenue growth, pressure on operating profitability and a weaker market valuation. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Cutera
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
46.5 M | 442 M | 686 M | 590 M | 349 M | 239 M | 625 M | 270 M | 165 M | 183 M | 150 M | 183 M | 130 M | - | - | - |
Shares |
19.9 M | 18.7 M | 17.9 M | 16.7 M | 14.1 M | 13.9 M | 13.9 M | 13.2 M | 14 M | 14.3 M | 14 M | 14.2 M | 13.9 M | 13.5 M | - | - |
Historical Prices |
2.34 | 23.6 | 38.4 | 35.3 | 24.8 | 17.1 | 45 | 20.4 | 11.8 | 12.8 | 10.7 | 12.9 | 9.35 | - | - | - |
Net Income |
-57.2 M | -7.79 M | 2.06 M | -23.9 M | -12.3 M | -30.8 M | 30 M | 2.58 M | -4.44 M | -10.6 M | -4.75 M | -6.55 M | -10.1 M | -10.5 M | -17.7 M | - |
Revenue |
49.5 M | 67.4 M | 231 M | 49.9 M | 51.8 M | 45.5 M | 47.6 M | 37.9 M | 94.8 M | 78.1 M | 74.6 M | 77.3 M | 60.3 M | 53.3 M | 53.7 M | - |
Cost of Revenue |
171 M | 113 M | 98.2 M | 21.9 M | 23 M | 26.7 M | 20.3 M | 16 M | 40.5 M | 34.8 M | 32.7 M | 35.7 M | 26 M | 23.1 M | 21.8 M | - |
Gross Profit |
-12.7 M | 38.7 M | 133 M | 75.8 M | 98.2 M | 80.4 M | 86.1 M | 68.1 M | 54.3 M | 43.4 M | 41.9 M | 41.5 M | 34.3 M | 30.2 M | 31.9 M | - |
Operating Income |
-156 M | -38.2 M | 1.83 M | -22.8 M | -12.1 M | -13.4 M | 11.1 M | 2.4 M | -4.52 M | -10.6 M | -5.26 M | -6.83 M | -10.4 M | -11.1 M | -10.3 M | - |
Interest Expense |
-244 K | -4.3 M | -2.42 M | 68 K | -199 K | - | - | - | - | 8 K | 105 K | 105 K | 614 K | 583 K | 1.57 M | - |
EBITDA |
-148 M | -32.4 M | 5.02 M | -18.8 M | -10.6 M | -12.2 M | 12.1 M | 3.38 M | -3.34 M | -9.28 M | -3.95 M | -5.22 M | -9.8 M | -10.4 M | -9.48 M | - |
Operating Expenses |
198 M | 178 M | 131 M | 98.6 M | 110 M | 93.8 M | 75 M | 65.7 M | 58.8 M | 54 M | 47.1 M | 48.4 M | 44.7 M | 41.3 M | 42.3 M | - |
General and Administrative Expenses |
63.3 M | 45.9 M | 32.9 M | 31.5 M | 24 M | 21 M | 14.1 M | 12.9 M | 12.1 M | 11.2 M | 9.94 M | 11.3 M | 10.1 M | 9.58 M | 10.3 M | - |
All numbers in USD currency
Quarterly Income Statement Cutera
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
20.2 M | 20.1 M | 20 M | 20 M | 19.9 M | 19.9 M | 19.8 M | 19.7 M | 19.6 M | 18.7 M | 18.1 M | 18 M | 17.9 M | 17.9 M | 17.8 M | 17.7 M | 17.6 M | 17.1 M | 14.4 M | 14.3 M | 14.2 M | 14.1 M | 14 M | 13.9 M | 13.9 M | 13.7 M | 13.6 M | 13.7 M | 14 M | 13.9 M | 13.8 M | 13.6 M | 13.2 M | 13.1 M | 13 M | 13 M | 13.8 K | 14.4 K | 14.6 K | 14.4 M | 14.3 M | 14.2 M | 14 M | 14 M | 14.5 M | 14.7 M | 14.4 M | 14.2 M | 14.1 M | 14.1 M | 14 M | 13.9 M | 13.9 M | 13.6 M | 13.7 M |
Net Income |
-39 M | -24.7 M | -22.8 M | - | -44.3 M | -33.3 M | -28 M | - | -12.1 M | -47.3 M | -15.1 M | - | -1.39 M | 7.75 M | -359 K | 2.19 M | -2.26 M | -11.4 M | -12.4 M | -2.09 M | -2.63 M | 588 K | -8.22 M | -26.3 M | -873 K | -1.57 M | -2.03 M | 22.9 M | 6.19 M | 1.95 M | -1.02 M | 4.21 M | 1.64 M | -1.23 M | -2.05 M | 2.05 M | -957 K | -1.89 M | -3.64 M | -1.62 M | -2.64 M | -2.74 M | -3.61 M | -278 K | -1.67 M | -638 K | -2.16 M | 1.08 M | -892 K | -1.47 M | -5.27 M | -887 K | -2.86 M | -2.46 M | -3.86 M |
Revenue |
32.5 M | 34.4 M | 38.8 M | - | 46.5 M | 61.8 M | 54.5 M | - | 62.8 M | 64.2 M | 58 M | - | 57.4 M | 58.6 M | 49.7 M | 49.9 M | 39.1 M | 26.4 M | 32.2 M | 51.8 M | 46.1 M | 47.8 M | 36 M | 45.5 M | 40.6 M | 42.6 M | 34.1 M | 47.6 M | 38.2 M | 36.4 M | 29.3 M | 37.9 M | 30.3 M | 27.5 M | 22.4 M | 30 M | 23.1 M | 22.6 M | 19.1 M | 25.5 M | 18.7 M | 17.7 M | 16.2 M | 22.2 M | 16.8 M | 19.6 M | 16 M | 22.5 M | 19.4 M | 19.6 M | 15.7 M | 18.5 M | 15.2 M | 14.9 M | 11.6 M |
Cost of Revenue |
30.7 M | 26.7 M | 26.4 M | - | 40 M | 35.7 M | 32.9 M | - | 28.6 M | 29.2 M | 26.2 M | - | 24 M | 24.8 M | 22 M | 21.9 M | 17.4 M | 14.7 M | 17.9 M | 23 M | 19.9 M | 21.9 M | 18.7 M | 26.7 M | 18.7 M | 20.2 M | 16.8 M | 20.3 M | 16 M | 15.3 M | 13.8 M | 16 M | 12.5 M | 11.5 M | 9.95 M | 12.1 M | 9.59 M | 9.69 M | 9.05 M | 11.7 M | 7.94 M | 7.85 M | 7.3 M | 9.2 M | 7.65 M | 8.44 M | 7.42 M | 9.79 M | 8.83 M | 9.27 M | 7.84 M | 7.51 M | 6.77 M | 6.48 M | 5.22 M |
Gross Profit |
1.81 M | 7.64 M | 12.4 M | - | 6.46 M | 26.1 M | 21.6 M | - | 34.2 M | 35 M | 31.8 M | - | 33.4 M | 33.8 M | 27.7 M | 28.1 M | 21.7 M | 11.6 M | 14.3 M | 28.8 M | 26.2 M | 25.8 M | 17.3 M | 18.8 M | 21.9 M | 22.4 M | 17.3 M | 27.3 M | 22.2 M | 21 M | 15.5 M | 21.9 M | 17.7 M | 16 M | 12.5 M | 17.9 M | 13.5 M | 12.9 M | 10 M | 13.8 M | 10.8 M | 9.88 M | 8.89 M | 13 M | 9.18 M | 11.1 M | 8.55 M | 12.7 M | 10.6 M | 10.3 M | 7.88 M | 11 M | 8.46 M | 8.42 M | 6.4 M |
Operating Income |
-36.2 M | -21.8 M | -19.4 M | - | -40.9 M | -31.2 M | -26.6 M | - | -9.43 M | -10.1 M | -13.2 M | - | 626 K | 2.07 M | 1.16 M | 1.44 M | -1.21 M | -10.9 M | -12.1 M | -1.93 M | -2.41 M | 299 K | -8.03 M | -5.49 M | -998 K | -2.16 M | -4.75 M | 4.54 M | 6.22 M | 1.73 M | -1.41 M | 4.44 M | 1.54 M | -1.42 M | -2.17 M | 2 M | -984 K | -1.93 M | -3.6 M | -1.59 M | -2.54 M | -2.84 M | -3.65 M | -340 K | -1.98 M | -623 K | -2.32 M | 1.07 M | -1.11 M | -1.52 M | -5.27 M | -934 K | -2.63 M | -2.86 M | -4.01 M |
Interest Expense |
575 K | -387 K | -1.32 M | - | -1.95 M | -453 K | -163 K | - | 265 K | -1.53 M | -755 K | - | -561 K | -392 K | 243 K | - | -382 K | 3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8 K | - | 138 K | 80 K | 105 K | 140 K | 75 K | 135 K | 105 K | 152 K | 144 K | 96 K | 140 K | 91 K | 199 K | 184 K |
EBITDA |
-36.2 M | -21.8 M | -19.4 M | - | -36.2 M | -27.2 M | -23 M | - | -8.24 M | -9 M | -12.1 M | - | 626 K | 2.07 M | 1.16 M | 1.44 M | -155 K | -10.2 M | -11.8 M | -1.93 M | -1.22 M | 1.11 M | -7.62 M | -5.49 M | -149 K | -1.61 M | -4.5 M | 4.54 M | 6.97 M | 2.22 M | -1.16 M | 4.44 M | 2.27 M | -932 K | -1.93 M | 2 M | -72 K | -1.31 M | -3.28 M | -1.59 M | -1.55 M | -2.18 M | -3.32 M | -340 K | -1 M | 23 K | -2 M | 1.07 M | 78 K | -753 K | -4.92 M | -934 K | -2.14 M | -2.54 M | -3.85 M |
Operating Expenses |
38 M | 29.4 M | 31.9 M | - | 47.4 M | 57.2 M | 48.2 M | - | 43.7 M | 45.1 M | 44.9 M | - | 32.8 M | 31.7 M | 26.5 M | 26.6 M | 23 M | 22.6 M | 26.5 M | 30.7 M | 28.6 M | 25.5 M | 25.3 M | 24.3 M | 22.9 M | 24.5 M | 22.1 M | 22.8 M | 16 M | 19.3 M | 16.9 M | 17.5 M | 16.2 M | 17.4 M | 14.6 M | 15.9 M | 14.5 M | 14.8 M | 13.6 M | 15.4 M | 13.3 M | 12.7 M | 12.5 M | 13.4 M | 11.2 M | 11.7 M | 10.9 M | 11.7 M | 11.7 M | 11.8 M | 13.1 M | 12 M | 11.1 M | 11.3 M | 10.4 M |
General and Administrative Expenses |
14.7 M | 4.32 M | 12.9 M | - | 17 M | 18.2 M | 12.3 M | - | 10.8 M | 11.2 M | 13.5 M | - | 7.81 M | 8.46 M | 7.36 M | 7.94 M | 7.24 M | 8.53 M | 7.81 M | 5.93 M | 7.31 M | 5.27 M | 5.52 M | 5.49 M | 5.16 M | 4.9 M | 5.44 M | 3.95 M | 3.38 M | 3.55 M | 3.22 M | 3.01 M | 2.72 M | 4 M | 3.22 M | 3.19 M | 2.94 M | 3.01 M | 2.99 M | 3.41 M | 2.9 M | 2.34 M | 2.56 M | 3.14 M | 2.16 M | 2.35 M | 2.29 M | 2.45 M | 2.48 M | 2.85 M | 3.5 M | 2.88 M | 2.31 M | 2.59 M | 2.33 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Cutera (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B |  USA |
 |
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.7 | 0.43 % | $ 770 M | USA |
 |
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | USA |
 |
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.53 | 2.76 % | $ 1.19 B | USA |
 |
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.35 | 0.08 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | USA |
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Apyx Medical Corporation
APYX
|
$ 2.95 | 1.37 % | $ 121 M | USA |
 |
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.23 | 1.0 % | $ 28.2 M | USA |
 |
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | Israel |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
InspireMD
NSPR
|
$ 0.74 | 0.16 % | $ 47.6 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | USA |
 |
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | USA |
 |
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M |  Australia |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Sensus Healthcare
SRTS
|
$ 3.03 | 0.32 % | $ 49.5 M | USA |
 |
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | USA |
 |
TELA Bio
TELA
|
$ 1.3 | 0.71 % | $ 61 M | USA |
 |
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |